Organon Launches REMS Program for Copper IUD Ahead of Late-2026 Rollout
Event summary
- Organon opens REMS certification program for MIUDELLA®, a hormone-free copper IUD, ahead of its anticipated commercial launch in late 2026.
- REMS training and certification are mandatory for healthcare providers, settings, and specialty pharmacies to dispense and insert MIUDELLA.
- MIUDELLA demonstrated 99% efficacy over three years in clinical trials involving 1,904 women aged 17 to 45.
- The REMS program aims to mitigate risks associated with improper insertion of the IUD.
The big picture
Organon’s proactive launch of the MIUDELLA REMS program underscores the strategic importance of training and certification in ensuring the safe adoption of new contraceptive technologies. The move aligns with broader industry trends toward stringent regulatory oversight for medical devices, particularly those involving procedural risks. With clinical trials demonstrating strong efficacy, Organon aims to carve out a niche in the women’s health sector, competing against established hormonal IUD options.
What we're watching
- Adoption Pace
- The pace at which healthcare providers and settings complete REMS certification will determine MIUDELLA’s market readiness by late 2026.
- Competitive Positioning
- Whether Organon can establish MIUDELLA as a leading hormone-free contraceptive option in a crowded IUD market.
- Regulatory Compliance
- How effectively the REMS program mitigates risks of improper insertion and ensures safe usage, avoiding potential regulatory scrutiny.
Related topics